Takeda's Kapidex DR launches in USA

The US subsidiary of Japan's largest drugmaker, Takeda Pharmaceuticals North America, says that Kapidex (dexlansoprazole) delayed-release  capsules are now available in pharmacies across the USA. Available in  30mg and 60mg doses, the drug was recently approved by the Food and Drug  Administration for the treatment of heartburn associated with  symptomatic non-erosive gastroesophageal reflux disease, the healing of  erosive esophagitis and the maintenance of healed EE.

The company claims that Kapidex is the first proton pump inhibitor with  a Dual Delayed Release formulation designed to provide two separate  releases of medication. PPIs work by turning off many of the acid pumps  in the stomach. The Takeda drug contains two types of enteric-coated  granules resulting in a concentration-time profile with two distinct  peaks: the first occurs one to two hours after administration, followed  by a second within four to five hours. In addition, the product can be  taken regardless of when food is consumed.